1
|
Wang J, Chen W, Lin H, Zhang J. [Role of miRNA-340 in modulating gastric cancer cell proliferation and bioinformatic analysis]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2019; 39:784-790. [PMID: 31340910 DOI: 10.12122/j.issn.1673-4254.2019.07.06] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
OBJECTIVE To investigate the mechanism of miRNA-340 for regulating the proliferation of gastric cancer (GC) cells and predict its interacting circular RNAs (circRNAs), its downstream target genes and the involved signaling pathways. METHODS The differentially expressed miRNAs in GC cell lines were analyzed and screened using miRNA microarrays. The expression level of miRNA-340 in 21 pairs of GC tissues and adjacent normal tissues was detected using real-time PCR. MTT and EdU assays were performed to examine the effect of miRNA-340 on the proliferation ability of HFE145 and BGC-823 cells. We also tested the effect of miRNA-340 inhibition on subcutaneous tumorigenesis of GC cells in a nude mouse model. The downstream target genes of miRNA-340 and the probable signal pathways were predicted online using Targetscan and DAVID database, respectively. The interacting circRNAs of miRNA-340 were analyzed using starBase platform. RESULTS Among the differentially expressed miRNAs, miRNA-340 was significantly down-regulated in GC cell lines. Real-time PCR results showed that the expression of miRNA-340 was significantly lower in GC tissues than in the adjacent tissues (P < 0.05). MTT and EdU cell proliferation assays showed that miRNA-340 overexpression inhibited the proliferation of GC cells in vitro. In the nude mouse models, the proliferation of GC cells transfected with miRNA-340 inhibitor was obviously enhanced. Bioinformatics analysis suggested that miRNA-340 had 21 target genes with 3 or more conserved sites, and these genes were involved in tumorigenesis and invasion. The top 10 circRNAs were selected as the most powerful sponge circRNAs interacting with miRNA-340. CONCLUSIONS miRNA-340 may play the role of a tumor suppressor in tumorigenesis and progression. Overexpression of miRNA-340 suppress the proliferation of GC cells, suggesting its involvement in the development of GC along with multiple circRNAs.
Collapse
Affiliation(s)
- Jian Wang
- Department of Pathology, Guangdong Women and Children's Hospital Affiliated to Guangzhou Medical University, Guangzhou 510000, China
| | - Wenjing Chen
- Department of Pathology, Guangdong Women and Children's Hospital Affiliated to Guangzhou Medical University, Guangzhou 510000, China
| | - Huijuan Lin
- Department of Pathology, Guangdong Women and Children's Hospital Affiliated to Guangzhou Medical University, Guangzhou 510000, China
| | - Jiangyu Zhang
- Department of Pathology, Guangdong Women and Children's Hospital Affiliated to Guangzhou Medical University, Guangzhou 510000, China
| |
Collapse
|
2
|
Yin G, Zhang B, Li J. miR‑221‑3p promotes the cell growth of non‑small cell lung cancer by targeting p27. Mol Med Rep 2019; 20:604-612. [PMID: 31180541 PMCID: PMC6580017 DOI: 10.3892/mmr.2019.10291] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Accepted: 02/21/2019] [Indexed: 01/19/2023] Open
Abstract
Emerging evidence suggests the critical function of microRNAs in regulating the growth of cancer cells. In the present study, it was demonstrated that miR-221-3p was overexpressed in non-small cell lung cancer (NSCLC) tissues and cell lines compared with that noted in the normal controls. Downregulation of miR-221-3p suppressed the proliferation, colony formation and invasion of NSCLC cells. To further understand the molecular mechanisms underlying the potential oncogenic function of miR-221-3p in NSCLC, the downstream targets of miR-221-3p were predicted using bioinformatic databases. The prediction suggested the cell cycle regulator p27 as one of the targets of miR-221-3p. Molecular experiments showed that miR-221-3p was able to bind with the 3′-untranslated region (UTR) of p27 and decreased the expression of p27 in NSCLC cells. Consistent with the suppressive role of p27 in controlling cell cycle progression, overexpression of miR-221-3p decreased the expression of p27 and promoted cell cycle progression from G1 to S phase. Collectively, our findings identified miR-221-3p as a novel regulator of NSCLC cell growth via modulating the expression of p27.
Collapse
Affiliation(s)
- Guoqing Yin
- Department of Oncology, Xianyang Hospital, Yan'an University, Xianyang, Shaanxi 712000, P.R. China
| | - Bo Zhang
- Radiation Department, People's Hospital of Ankang City, Ankang, Shaanxi 725000, P.R. China
| | - Jia Li
- Department of Respiratory Medicine, Longnan Hospital, Daqing, Heilongjiang 163453, P.R. China
| |
Collapse
|
3
|
Xie L, Chen Z, Liu H, Guan L, Wang Z, Li W. Effects of miR-340 on hepatocellular carcinoma by targeting the DcR3 gene. Dig Liver Dis 2018; 50:291-296. [PMID: 29311025 DOI: 10.1016/j.dld.2017.10.024] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Revised: 10/18/2017] [Accepted: 10/29/2017] [Indexed: 12/11/2022]
Abstract
In hepatocellular carcinoma (HCC), miR-340 plays a vital role in the regulation of tumor occurrence and deterioration, while DcR3 gene is involved in cancer cell proliferation and apoptosis. This study analyzed miR-340 in the serum of patients with HCC and healthy controls. Then, miR-340, DcR3, TGF-β1 and Smad2 expression were measured in HCC tissues and adjacent parts. Relationship between miR-340 and DcR3 was verified. Effects of miR-340 on human HepG2 cell proliferation and apoptosis were explored. miR-340, DcR3, TGF-β1, Smad2 mRNA and protein expression were also determined after miR-340 transfection. Compared with the control, miR-340 was significantly lower in the serum of the HCC patients (p < 0.01). miR-340 was lower in HCC tissues than in adjacent; however, DcR3, TGF-β1 and Smad2 were higher (p < 0.01). Furthermore, luciferase activity was significantly lower in the cells co-transfected with miR-340 mimics and DcR3-3'UTR-WT (p < 0.01), indicating that DcR3 was a target gene of miR-340. Moreover, decreased expression in DcR3, TGF-β1 and Smad2 was detected after miR-340 overexpression (p < 0.01), thus promoting apoptosis and blocking the proliferation of human HepG2 cells (p < 0.05). Furthermore, overexpression of DcR3 could activate the TGF-β1/Smad2 signal transduction pathway and increase the phosphorylation of Smad2. In conclusion, miR-340 plays a suppressive role in HCC development by targeting DcR3 and silencing the TGF-β1/Smad2 signaling pathway.
Collapse
Affiliation(s)
- Lijuan Xie
- Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Zhuo Chen
- Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Hongyu Liu
- Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Lianyue Guan
- Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Zhanpeng Wang
- Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Wei Li
- Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
| |
Collapse
|
4
|
Poenitzsch Strong AM, Berry SM, Beebe DJ, Li JL, Spiegelman VS. miFAST: A novel and rapid microRNA target capture method. Mol Carcinog 2018; 57:559-566. [PMID: 29350431 DOI: 10.1002/mc.22780] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 12/30/2017] [Accepted: 01/02/2018] [Indexed: 12/23/2022]
Abstract
MicroRNAs (miRNAs), small 22-25 nucleotide non-coding RNAs, play important roles in cellular and tumor biology. However, characterizing miRNA function remains challenging due to an abundance of predicted targets and an experimental bottleneck in identifying biologically relevant direct targets. Here, we developed a novel technique (miFAST) to identify direct miRNA target genes. Using miFAST, we confirmed several previously reported miR-340 target genes and identified five additional novel direct miR-340 targets in melanoma cells. This methodology can also be efficiently applied for the global characterization of miRNA targets. Utilizing miFAST to characterize direct miRNA targetomes will further our understanding of miRNA biology and function.
Collapse
Affiliation(s)
| | - Scott M Berry
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin
| | - David J Beebe
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin
| | - Jian-Liang Li
- Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida
| | - Vladimir S Spiegelman
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Pennsylvania State University, College of Medicine, Hershey, Pennsylvania
| |
Collapse
|
5
|
Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, Zhang Z, Zhou Q. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma. ACTA ACUST UNITED AC 2017; 50:e6359. [PMID: 28443990 PMCID: PMC5441287 DOI: 10.1590/1414-431x20176359] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Accepted: 03/02/2017] [Indexed: 02/07/2023]
Abstract
MicroRNAs (miRNAs) play an important role in drug resistance and modulate the efficiency of chemotherapy. A recent study indicated that miR-340 functions as a tumor suppressor in various types of cancer. However, the role of miR-340 in chemotherapy has not been reported yet. In this study, we found that miR-340 enhanced cisplatin (CDDP)-induced cell death. Induction of miR-340-5p expression decreased the IC50 of CDDP and increased the apoptosis of CDDP-resistant MG-63 and Saos-2 cells. Moreover, miR-340-5p decreased the accumulation of MRP1 and MDR1. We further explored the mechanism underlying the promoting effects of miR-340-5p on CDDP-induced cell death. We identified a potential target of miR-340 in the 3' untranslated region of lysophosphatidic acid acyltransferase (LPAATβ) using the online program Targetscan (http://www.microrna.org). Luciferase reporter assays showed that miR-340 binds to the 3'UTR of LPAATβ. Enforced expression of miR-340-5p decreased the accumulation of LPAATβ in both MG-63 and Saos-2 cells. Silencing LPAATβ decreased the IC50 of CDDP and increased the apoptosis of CDDP-resistant MG-63 and Saos-2 cells, which is consistent with the effect of miR-340-5p on CDDP-induced cell death. Moreover, induced expression of LPAATβ compromised the effects of miR-340-5p on CDDP-induced cell death and accumulation of MRP1 and MDR1. Taken together, our data indicated that miR-340-5p enhanced the sensitivity to CDDP by targeting LPAATβ.
Collapse
Affiliation(s)
- L Song
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - P Duan
- Southwest Eye Hospital, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - Y Gan
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - P Li
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - C Zhao
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - J Xu
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - Z Zhang
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| | - Q Zhou
- Department of Orthopedics, First Affiliated Hospital, Third Military Medical University, Chongqing, China
| |
Collapse
|
6
|
Xue J, Yang J, Luo M, Cho WC, Liu X. MicroRNA-targeted therapeutics for lung cancer treatment. Expert Opin Drug Discov 2016; 12:141-157. [PMID: 27866431 DOI: 10.1080/17460441.2017.1263298] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
INTRODUCTION Lung cancer is one of the leading causes of cancer-related mortality worldwide. MicroRNAs (miRNAs) are endogenous non-coding small RNAs that repress the expression of a broad array of target genes. Many efforts have been made to therapeutically target miRNAs in cancer treatments using miRNA mimics and miRNA antagonists. Areas covered: This article summarizes the recent findings with the role of miRNAs in lung cancer, and discusses the potential and challenges of developing miRNA-targeted therapeutics in this dreadful disease. Expert opinion: The development of miRNA-targeted therapeutics has become an important anti-cancer strategy. Results from both preclinical and clinical trials of microRNA replacement therapy have shown some promise in cancer treatment. However, some obstacles, including drug delivery, specificity, off-target effect, toxicity mediation, immunological activation and dosage determination should be addressed. Several delivery strategies have been employed, including naked oligonucleotides, liposomes, aptamer-conjugates, nanoparticles and viral vectors. However, delivery remains a main challenge in miRNA-targeting therapeutics. Furthermore, immune-related serious adverse events are also a concern, which indicates the complexity of miRNA-based therapy in clinical settings.
Collapse
Affiliation(s)
- Jing Xue
- a Center of Laboratory Medicine , General Hospital of Ningxia Medical University , Yinchuan , China.,b College of Life Science , Ningxia University , Yinchuan , China
| | - Jiali Yang
- a Center of Laboratory Medicine , General Hospital of Ningxia Medical University , Yinchuan , China
| | - Meihui Luo
- a Center of Laboratory Medicine , General Hospital of Ningxia Medical University , Yinchuan , China
| | - William C Cho
- c Department of Clinical Oncology , Queen Elizabeth Hospital , Kowloon , Hong Kong
| | - Xiaoming Liu
- a Center of Laboratory Medicine , General Hospital of Ningxia Medical University , Yinchuan , China.,b College of Life Science , Ningxia University , Yinchuan , China.,d Human Stem Cell Institute , General Hospital of Ningxia Medical University , Yinchuan , Ningxia , China
| |
Collapse
|